UPDATE: Stifel Nicolaus Initiates Buy, $29 Target on BioSpecifics Technologies

Stifel Nicolaus initiates its coverage on BioSpecifics Technologies BSTC with a Buy rating and a price target of $29 on upside potential from Ziaflex. Stifel Nicolaus says, "We view Biospecfics as a low-risk way to benefit from a potential Xiaflex resurgence. With little at risk in the form of committed R&D funding, BSTC investors are positioned to benefit from potential upside in the Xiaflex franchise via an 8.5% share of milestone payments and an approximate 10.5% royalty on sales. We estimate royalty revenue of $11.5 million in 2012, driving EPS of $0.84." BSTC closed at $17.36 a share on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetInitiationIntraday UpdateAnalyst RatingsStifel Nicolaus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!